Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Plus Ibrutinib in T-Cell Prolymphocytic Leukemia
NCT03873493Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of venetoclax, ibrutinib in T-cell prolymphocytic leukemia (T-PLL), sponsored by AbbVie Inc.. Started Jan 2020; status: completed.
02
Drugs
venetoclaxibrutinib
03
Conditions
T-cell prolymphocytic leukemia (T-PLL)
Beyond the preview
Go deeper on NCT03873493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03873493.